A significant portion of patients with multiple sclerosis (MS) can achieve a stable disease state when treated with modern disease-modifying therapy (DMT), especially when started early in the ...

Adults with relapsing MS rated the Sensoready pen, an autoinjector used to self-administer Kesimpta, for ease of use and ...

The following is a summary of “Real-world satisfaction and experience with injection and autoinjector device for ofatumumab ...

Multiple sclerosis (MS) is an inflammatory autoimmune ... was approved in 1993 as the first DMT for relapsing-remitting MS. AVONEX was approved for relapsing forms of MS in 1996.

19 The first oral treatment, fingolimod, was introduced in 2010; it is also the only DMT approved for the treatment of MS in pediatric patients aged over 10 years. 19,22 Fingolimod is an analogue ...

According to the National Cancer Institute, approximately 40.5% of Americans will be diagnosed with cancer at some point ...

The first clinical consensus statement for managing multiple sclerosis (MS) in Australia and New Zealand has been released, ...

Multiple sclerosis (MS) is one of the most widespread ... advances in a disease-modifying therapy (DMT) for MS may actually slow down the progression. However, it is too soon to tell by how ...

Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...

ECTRIMS and EBMT said stem cell transplant can be considered for some with RRMS, such as those who are younger and have less ...

In multiple sclerosis (MS), a person's immune system attacks the protective covering (myelin sheath) of nerve fibers in the brain and spinal cord (central nervous system). MS disease-modifying ...